Board Member
Lisata Therapeutics, Inc. (LSTA)Equibles does not estimate personal net worth.
Get an email with a short summary when Lisata Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get LSTA alertsDavid Mazzo is recorded as Board Member at Lisata Therapeutics, Inc. (LSTA) since January 1, 2015. The newest filing on record that lists David Mazzo as Board Member at Lisata Therapeutics, Inc. (LSTA) is dated April 25, 2025. Lisata Therapeutics, Inc. reported in an 8-K filed September 15, 2022 that David Mazzo was appointed Director, effective September 15, 2022. The proxy statement of Lisata Therapeutics, Inc. reports total compensation of $1,691,174 for David Mazzo in fiscal 2024, including a base salary of $702,969. Disclosed compensation is on record for 7 fiscal years. David Mazzo has spoken on 21 earnings calls across 1 company, most recently for Lisata Therapeutics, Inc. on November 6, 2025. Lisata Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Lisata Therapeutics, Inc. includes David J. Mazzo (CEO and Board Member), David J. Mazzo, Ph.D. (CEO), Gregory Brown (Chairman) and 7 others.
“three Caladrius directors, including David Mazzo, Ph.D., Cynthia Flowers, and Steve Klosk, will continue as directors on Lisata’s Board.”
“It's my pleasure to provide the latest update of Losada's recent business highlights, discuss our third quarter 2025 financial results, and give a report on the progress of our development programs.”
“Unfortunately, John is having technical difficulties and hasn't been able to join the call, and some of the other speakers have also been having some issues today, so we apologize for any inconsistent sound, and we hope that you'll be able to hear the webcast at a later date.”
“It's a pleasure to be here again to provide an overview of Lisata's recent business highlights, discuss our first quarter 2025 financial results, and give an update on the progress of our development programs.”
“It is my pleasure to be here today to provide an overview of recent business highlights, discuss our third quarter 2024 financial results, and give an update on the progress of our development programs.”
“I'm delighted to be with you today to provide an overview of recent business highlights, discuss our second quarter 2024 financial results and provide an update on the progress of our clinical development programs.”
2015-01-01–present
Last confirmed April 25, 2025
Start not stated–2025-04-25
Last confirmed by a filing; no departure on record
Biotechnology · Healthcare
Board Member
2015-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Lisata Therapeutics, Inc. (LSTA) | President and Chief Executive Officer | $702,969 | $1,691,174 |
| 2023 | Lisata Therapeutics, Inc. (LSTA) | President and Chief Executive Officer | $675,931 | $1,408,382 |
| 2022 | Lisata Therapeutics, Inc. (LSTA) | President and Chief Executive Officer | $650,441 | $1,929,933 |
| 2021 | Lisata Therapeutics, Inc. (LSTA) | Chief Executive Officer | $631,495 | $1,335,216 |
| 2020 | Lisata Therapeutics, Inc. (LSTA) | President and Chief Executive Officer | $613,102 | $1,435,031 |
| 2019 | Lisata Therapeutics, Inc. (LSTA) | President and Chief Executive Officer | $596,693 | $1,539,651 |
| 2018 | Lisata Therapeutics, Inc. (LSTA) | President and Chief Executive Officer | $593,796 | $1,892,242 |
